FDA Grants Breakthrough Device Designation to Augurex's SPINEstat Test for Axial Spondyloarthritis Diagnosis
核心洞察
The FDA has granted breakthrough device designation to Augurex Life Sciences (搜索)' SPINEstat (搜索) 14-3-3eta Autoantibody Multiplex Immunoassay Test for diagnosing axial spondyloarthritis (搜索) (axSpA (搜索)).
The test addresses a significant diagnostic gap, as axSpA (搜索) patients typically face seven to ten years of diagnostic delays and are often misdiagnosed with mechanical back pain (搜索).
SPINEstat (搜索) measures autoantibodies to the 14-3-3eta protein (搜索) and demonstrated high specificity and sensitivity in differentiating axSpA (搜索) from mechanical back pain (搜索) at the ACR Convergence conference.
The US Food and Drug Administration has granted breakthrough device designation to Augurex Life Sciences (搜索)' SPINEstat (搜索) 14-3-3eta Autoantibody Multiplex Immunoassay Test for diagnosing axial spondyloarthritis (搜索) (axSpA (搜索)), marking a significant advancement in addressing diagnostic challenges for this debilitating autoimmune condition.
The designation recognizes the potential of this first-in-class diagnostic test to address a large unmet need in the early and accurate differentiation of axSpA (搜索) within the broader chronic back pain (搜索) population. Already approved in the UK and Canada, SPINEstat (搜索) is designed to diagnose this autoimmune condition that causes persistent back pain, primarily affecting adults under the age of 45 years.
Addressing Critical Diagnostic Delays
AxSpA (搜索) is a chronic and degenerative autoimmune disease that affects millions of people worldwide. Despite its prevalence, patients often face significant diagnostic delays averaging seven to ten years, as many patients are misdiagnosed with mechanical back pain (搜索), resulting in delayed therapeutic intervention and irreversible spinal damage.
The disease is often mistaken for common low back pain, leading to misdiagnosis. Without proper treatment, axSpA (搜索) can result in decreased spinal mobility and even fusion of the vertebrae.
Test Mechanism and Clinical Performance
SPINEstat (搜索) operates as a multiplex immunoassay that measures autoantibodies to the 14-3-3eta protein (搜索). Recent data presented at the American College of Rheumatology (ACR) Convergence conference highlighted the test's high specificity and sensitivity in differentiating axSpA (搜索) from mechanical back pain (搜索).
The test is designed to complement existing diagnostic tools, as well as signs, symptoms, and clinical findings, to aid in improved clinical decision-making and expedited referrals to rheumatology care. When combined with clinical findings, signs and symptoms consistent with axSpA (搜索), SPINEstat (搜索) is intended to aid in the diagnosis of patients with axSpA.
Commercial Strategy and Regulatory Path
Augurex plans to collaborate with the US regulator to expedite the regulatory review process for the test. Concurrently, the company is working on widening the test's availability as analyte specific reagents (ASRs) and general-purpose reagents (GPRs) under the laboratory-developed test in the US.
This strategy aligns with broader commercial launches planned for the UK, Canada, and other international markets, where the test is already approved and available.
Industry Impact
"Receiving FDA Breakthrough Designation for SPINEstat (搜索) marks a major milestone for Augurex and an important step forward for patients living with inflammatory back pain," said Neil Klompas, Chief Executive Officer of Augurex Life Sciences (搜索). "This recognition from the FDA underscores the potential of SPINEstat to close a long-standing diagnostic gap for this debilitating condition by providing patients and physicians with a new objective and specific tool to differentiate axSpA (搜索) from mechanical back pain (搜索) and access the appropriate medical care."
The breakthrough designation underscores Augurex's commitment to advancing novel autoimmune diagnostic solutions and improving early and accurate disease detection in areas of high unmet medical need. The company remains focused on expanding access to innovative biomarker-based diagnostics that enable earlier and more accurate detection of autoimmune and inflammatory diseases, including axSpA (搜索).